


LQZ-7F

Chemical Properties

CAS No. : 354543-09-2
Formula: C₁₄H₇N₉O₃
Molecular Weight: 349.26
Appearance: no data available
Storage: store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year



Biological Description

Description	LQZ-7F is a small molecule survivin dimerisation inhibitor with anticancer activity. LQZ-7F induces proteasome-dependent survivin degradation, mitotic arrest, and apoptosis, and blocks human tumour growth in mouse xenograft assays.
Targets(IC50)	Apoptosis, Survivin
In vitro	LQZ-7F and LQZ-7F1 treatment at 2.5 µM for 72 hours inhibited the viability of prostate cancer cell lines PC-3 and C4-2, as determined by MTT assay.
In vivo	LQZ-7F was administered at 25 mg/kg via intraperitoneal injection once every 3 days for a total of 8 treatments. On the 30th day after treatment, it was found to inhibit the growth of xenograft tumors[1].

Solubility Information

Solubility	DMSO: 2 mg/mL (5.73 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.8632 mL	14.316 mL	28.632 mL
5 mM	0.5726 mL	2.8632 mL	5.7264 mL
10 mM	0.2863 mL	1.4316 mL	2.8632 mL
50 mM	0.0573 mL	0.2863 mL	0.5726 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Robert Peery, et al. A novel survivin dimerization inhibitor without a labile hydrazone linker induces spontaneous apoptosis and synergizes with docetaxel in prostate cancer cells. Bioorg Med Chem. 2022 Jul 1;65:116761.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481